Ricerc@Sapienza

OBJECTIVE: To investigate the association of cancer stem cell biomarker aldehyde dehydrogenase-1 (ALDH1) with ovarian cancer patients' prognosis and clinico-pathological characteristics.
METHODS: The electronic searches were performed in January 2018 through the databases PubMed, MEDLINE and Scopus by searching the terms: "ovarian cancer" AND "immunohistochemistry" AND ["aldehyde dehydrogenase-1" OR "ALDH1" OR "cancer stem cell"]. Studies evaluating the impact of ALDH1 expression on ovarian cancer survival and clinico-pathological variables were selected.

Background: High-grade serous ovarian cancer (HGSOC) causes 80% of all
ovarian cancer (OC) deaths. In this setting, the role of cancer stem-like cells (CSCs) is still unclear.
In particular, the evolution of CSC biomarkers from primary (pOC) to recurrent (rOC)
HGSOCs is unknown. Aim of this study was to investigate changes in CD133 and aldehyde
dehydrogenase-1 (ALDH1) CSC biomarker expression in pOC and rOC HGSOCs.
Methods: Two-hundred and twenty-four pOC and rOC intrapatient paired tissue samples